Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients


30 Sep 2019


Poster Display session 3



Tumour Site


Shinichi Kageyama


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


S. Kageyama1, Y. Nagata2, T. Ishikawa3, T. Abe4, M. Murakami5, T. Kojima6, K. Taniguchi7, H. Shimada8, S. Hirano9, S. Ueda10, K. Kanetaka11, H. Wada12, H. Yamaue13, E. Sato14, Y. Miyahara15, N. Goshima16, H. Ikeda17, T. Yamada18, M. Osako19, H. Shiku1

Author affiliations

  • 1 Department Of Immuno-gene Therapy, Mie University, 514-8507 - Tsu/JP
  • 2 Comprehensive Community Care Education, Nagasaki University, 852-8523 - Nagasaki/JP
  • 3 Department Of Gastroenterology And Hepatology, Kyoto Prefectural University of Medicine, 602-8566 - Kyoto/JP
  • 4 Department Of Gastroenterological Surgery, Aichi Cancer Center, Nagoya/JP
  • 5 Department Of Gastroenterological And General Surgery, Showa University, Tokyo/JP
  • 6 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 7 Department Of Surgery, Nagasaki Medical Center, Ohmura/JP
  • 8 Department Of Gastroenterological Surgery, Toho University, Tokyo/JP
  • 9 Department Of Gastroenterological Surgery, Hokkaido University, Sapporo/JP
  • 10 Department Of Gastroenterological Surgery And Oncology, Kitano Hospital, Osaka/JP
  • 11 Department Of Surgery, Nagasaki University, 852-8523 - Nagasaki/JP
  • 12 Department Of Gastroenterological Surgery, Osaska University, Suita/JP
  • 13 Second Department Of Surgery, Wakayama Medical University, 641-8509 - Wakayama/JP
  • 14 Department Of Human Pathology, Tokyo Medical University, Tokyo/JP
  • 15 Department Of Personalized Cancer Immunotherapy, Mie University, 514-8507 - Tsu/JP
  • 16 Molecular Profiling Research Center For Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo/JP
  • 17 Department Of Oncology, Nagasaki University, 852-8523 - Nagasaki/JP
  • 18 Medical Center For Translational And Clinical Research, Osaska University, Suita/JP
  • 19 Data Management, FiveRings CO., Osaka/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1631


Since PD-1/PD-L1 blockade has displayed clinical efficacy in esophageal cancer patients, an immunological therapeutic approach such as a cancer vaccine will be realistic in clinics. NY-ESO-1, one of cancer-testis antigens, is expressed in approximately 30% esophageal squamous cell carcinoma (ESCC). Cholesteryl pullulan (CHP) is an antigen delivery system to antigen-presenting cells including macrophages. The complex of CHP and NY-ESO-1 protein (CHP-NY-ESO-1) is a vaccine that activates CD4+ and CD8+ T cells. We aimed to evaluate clinical efficacy of the CHP-NY-ESO-1 for esophageal cancer patients after radical surgery in a randomized phase II trial.


54 NY-ESO-1-expressing ESCC patients who underwent radical surgery following neoadjuvant chemotherapy of cisplatin/5-FU were randomized to two arms, CHP-NY-ESO-1 vaccine and observation as a control arm. The vaccine was composed of 200 mg full-length NY-ESO-1 protein, which was subcutaneously given 15 doses with 2 or 4-week interval for 12 months. Primary endpoints were disease-free survival (DFS) and safety. Secondary endpoints were immune-responses and overall survival (OS). 49 patients were evaluated for DFS and OS.


DFS in 2 years are 56.0% and 58.3% in the vaccine arm and in the control. OS in 2 years are 76.0% and 79.2%, respectively. No differences were seen between the vaccine and the control group. Subgroup analysis demonstrated that T-bet+ CD8+ T cell infiltration was significantly correlated to DFS and that PD-L1-expression in tumors showed unfavorable tendency for the vaccine group. Exploratory analysis of intra-cohort correlations among the vaccinated patients revealed that 5% or more expression of NY-ESO-1 and high polymeric immunoglobulin receptor (PIGR)-gene expression in tumors were favorable factors.


The clinical trial revealed that CHP-NY-ESO-1 vaccine alone did not display clinical efficacy compared to the control. It suggested that CHP-NY-ESO-1 vaccine would be indicated to > 5% NY-ESO-1 and/or high PIGR gene-expressing esophageal tumors that are infiltrated with activated T cells.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Japan Agency for Medical Research and Development.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.